Results 51 to 60 of about 248,205 (145)

B-cell chronic lymphocytic leukemia-associated nuclear antigens [PDF]

, 2008
One- and two-dimensional polyacrylamide gel electrophoresis were used to compare the composition of nuclear polypeptides from normal and В-cell chronic lymphocytic leukemia mononuclear cells.
Błoński, Jerzy Z., Kiliańska, Zofia M., Robak, Tadeusz, Rogalinska, Malgorzata   +3 more
core  

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis [PDF]

, 2017
Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant CD5(+) B lymphocytes in blood, bone marrow and lymphoid organs. CD1d-restricted invariant Natural Killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in
Azzimonti, Laura, Bellone, Matteo, Bertilaccio, Maria Teresa, Caligaris Cappio, Federico, Capri, Miriam, Casorati, Giulia, de Lalla, Claudia, Delfanti, Gloria, Dellabona, Paolo, DI NAPOLI, Arianna, Doglioni, Claudio, Franceschi, Claudio, Ghia, Paolo, Gorini, Francesca, Gulino, Alessandro, Ranghetti, Pamela, Scarfò, Lydia, Scielzo, Cristina   +17 more
core   +1 more source

Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia : implication for therapy [PDF]

, 2017
This work was supported by: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 x mille n.9980, (to M.F., F.M. A. N., P.T. and M.N.) ; AIRC I.G. n. 14326 (to M.F.), n.10136 and 16722 (A.N.), n.15426 (to F.F.).
Baio, G., Basso, L., Boccardo, S., Calabrese, M., Cilli, M., Colombo, M., Cutrona, G., Emionite, L., Fabris, S., Fais, F., Ferrarini, M., Gentile, M., Massara, R ., Massucco, C., Matis, S., Morabito, F., Negrini, M., Neri, A., Neumaier, C. E., Recchia, A. G., Reverberi, D., Rosa, F., Salvi, S., Tassone, P., Truini, M., Valdora, F., Zupo, S.   +26 more
core   +1 more source

Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens. [PDF]

, 2015
BackgroundTo determine differentially expressed and spliced RNA transcripts in chronic lymphocytic leukemia specimens a high throughput RNA-sequencing (HTS RNA-seq) analysis was performed.MethodsTen CLL specimens and five normal peripheral blood CD19+ B ...
A Ameur, A Choudhury, A Hidalgo, A Rosenwald, AS Kamiguti, C Haslinger, C Soo, C Trapnell, C Trapnell, CJ David, DC Gilby, E Moon, E Moravcikova, F Colotta, F Talab, FC Kelleher, Gwen Jordaan, H Dohner, H Jiang, J Eswaran, J Vilpo, JC Marioni, JJ Dongen van, JP Venables, K Inada, K Zen, L Chen, L Wang, L Yang, LQ Zhang, M Crespo, M Rehli, M Shinohara, M Sultan, Matteo Pelegrini, ML Hermiston, MW Pfaffl, N Chiorazzi, NA Twine, O Bermudez, P Guglielmi, P Kapranov, PG Ferreira, Phillipp Nham, Q Huang, RA Higgins, RI Fernando, RK Gandhirajan, RN Damle, Ryan T. Phan, S Anders, S Courtois, S Decker, S Falt, S Ibrahim, S Liu, S Ma, S Ren, S Shen, Sanjai Sharma, SM Russell, SP Shah, SR Gunn, T Ormsby, TJ Hamblin, U Klein, V Quesada, Wei Liao, XS Puente, Y Pawitan, Y Pekarsky, Y Yu, Z Wang   +72 more
core   +1 more source

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

Leukemia, 2018
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome.
J. Malcikova, J. Malcikova, E. Tausch, Davide Rossi, L. Sutton, L. Sutton, Thierry Soussi, Thierry Soussi, Thierry Soussi, T. Zenz, A. Kater, C. Niemann, David Gonzalez, Frédéric Davi, M. G. Diaz, Carol Moreno, G. Gaidano, K. Stamatopoulos, Richard Rosenquist, Richard Rosenquist, S. Stilgenbauer, P. Ghia, Š. Pospíšilová, Š. Pospíšilová   +23 more
semanticscholar   +1 more source

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. [PDF]

, 2017
ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL).
A Butrym, A Stacchini, AH Daneshmanesh, AM Brunati, B Cui, C Scielzo, C Scielzo, C Wilson, D Kitamura, DA Dehring, E Roszmusz, E Ten Hacken, E ten Hacken, ES Witze, F Frezzato, GF Widhopf II, HE Broome, J Skokowa, J Yu, J Yu, JA Burger, JA Di Paolo, JJ Hao, K Alexandropoulos, K Kurokawa, M Lettau, M Muzio, M Rodriguez-Niedenfuhr, MY Choi, N Martinez-Quiles, P Masiakowski, P Masiakowski, PJ Cavnar, S Baskar, S Mukherjee, T Fukuda, T Uruno, TS Gomez, WC Forrester, WC Forrester, X Qi, Y Suzuki, Y Takemoto, Y Yamanashi, YK Xu, Z Weng   +45 more
core   +1 more source

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Journal of Clinical Oncology, 2019
PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax).
P. Hillmen, A. Rawstron, K. Brock, Samuel Muñoz-Vicente, F. Yates, R. Bishop, Rebecca Boucher, D. Macdonald, C. Fegan, Alison M. McCaig, A. Schuh, A. Pettitt, J. Gribben, P. Patten, S. Devereux, A. Bloor, C. Fox, F. Forconi, T. Munir   +18 more
semanticscholar   +1 more source

Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia [PDF]

, 2017
Telomeres are protective repeats of TTAGGG sequences located at the end of human chromosomes. They are essential to maintain chromosomal integrity and genome stability.
Bezares, Raimundo F., Dos Santos, Patricia Carolina, Palau Nagore, Maria Virginia, Panero, Julieta, Slavutsky, Irma Rosa, Stanganelli, Carmen Graciela, Stella, Flavia   +6 more
core   +1 more source

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Journal of Clinical Oncology, 2017
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib.
C. Turtle, K. Hay, L. Hanafi, Daniel H. Li, S. Cherian, Xueyan Chen, B. Wood, A. Lozanski, J. Byrd, S. Heimfeld, S. Riddell, D. Maloney   +11 more
semanticscholar   +1 more source

Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. [PDF]

, 2009
We observed that high-dose methylprednisolone (HDMP) and rituximab was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL).
Bole, J, Castro, JE, Jain, S, James, DF, Kipps, TJ, Rassenti, L, Sandoval-Sus, JD   +6 more
core